NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced today that it has signed a co-development agreement with PathGroup for the PGDx Elio tissue-based complete assay.
As part of the agreement, the firms will partner on the necessary studies to support and secure US regulatory approval for the Elio tissue complete assay. PathGroup said it plans to be the first US laboratory to use the Elio panel.